Domestic Manufacturing Revitalization Act of 2026
Summary
Senator Cassidy introduced the Domestic Manufacturing Revitalization Act of 2026, which would create a pilot program to incentivize hospitals to purchase domestic PPE and medical consumables. The bill is in early stage, referred to Finance Committee, with no cosponsors and no authorized funding. Near-term market impact is minimal.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The bill is in early stage with no funding authorized.
- 2.Domestic PPE and medical consumable manufacturers are potential beneficiaries but impact is minimal.
- 3.No cosponsors and referral to Finance Committee suggest low priority.
Market Implications
The bill has no immediate market implications. If enacted with funding, domestic medical supply manufacturers like , , and could see a modest increase in demand from hospitals. However, given the voluntary nature and lack of appropriations, the effect is negligible. The broader trend of reshoring medical supply chains may provide tailwinds, but this specific bill does not move the needle.
Full Analysis
The Domestic Manufacturing Revitalization Act of 2026 (S.5513) was introduced on September 24, 2026, and referred to the Committee on Finance. The bill would amend the Social Security Act to establish a pilot program where hospitals receiving above-average Medicare payments can voluntarily agree to purchase at least 40% of their PPE and medical consumables from domestic sources. The Secretary of Health and Human Services would have discretion to adjust the percentage during supply chain disruptions. No funding is authorized in the bill; any implementation would require subsequent appropriations. The bill has no cosponsors and is sponsored by a junior senator, indicating low legislative momentum. The primary potential beneficiaries are domestic manufacturers of PPE and medical consumables, such as 3M, Cardinal Health, Becton Dickinson, Kimberly-Clark, and DuPont. However, because the program is voluntary and unfunded, the actual impact on these companies' revenues is negligible at this stage. Hospitals face no mandate and no financial incentive to change purchasing behavior. The bill is unlikely to advance without significant amendments and appropriations. Investors should monitor for committee action or companion bills in the House, but currently this is a low-impact signal.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
MULTIPLE RECIPIENTS: $1.7B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $5.6B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $3.2B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $6.1B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $1.8B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $1.4B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $2.2B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $1.1B Department of Health and Human Services Federal Award
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Restoring Reciprocity in Government Procurement
This Presidential Memorandum directs the Office of Management and Budget, the U.S. Trade Representative, and other federal agencies to identify and remove Canadian-origin items from federal civil procurement where possible, citing Canada's 'Buy Canadian' policies as discriminatory. It also requires agencies to be notified of domestic alternatives and mandates ongoing monitoring of Canada's procurement practices, with provisions for restoring access if Canada changes its policies.
Excluding Certain Canadian Alcoholic Beverages from Importation into the United States in Response to Continued Discrimination Against the Commerce of the United States with Respect to Alcoholic Beverages
President Trump, invoking Section 338 of the Tariff Act of 1930, orders an import ban on certain Canadian alcoholic beverages effective September 29, 2026, escalating previous 50% ad valorem duties. This action targets Canadian discrimination against U.S. alcoholic beverages, citing Canada's broken commitments and additional retaliation. The ban replaces the tariff for specified products with a complete exclusion from entry into the United States.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →